<SEC-DOCUMENT>0001279569-19-002396.txt : 20191125
<SEC-HEADER>0001279569-19-002396.hdr.sgml : 20191125
<ACCEPTANCE-DATETIME>20191125164839
ACCESSION NUMBER:		0001279569-19-002396
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191125
FILED AS OF DATE:		20191125
DATE AS OF CHANGE:		20191125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Canopy Growth Corp
		CENTRAL INDEX KEY:			0001737927
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38496
		FILM NUMBER:		191246751

	BUSINESS ADDRESS:	
		STREET 1:		1 HERSHEY DRIVE
		CITY:			SMITH FALLS
		STATE:			A6
		ZIP:			K7A0A8
		BUSINESS PHONE:		855-558-9333

	MAIL ADDRESS:	
		STREET 1:		1 HERSHEY DRIVE
		CITY:			SMITH FALLS
		STATE:			A6
		ZIP:			K7A0A8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>canopy6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD></HEAD>
<TITLE></TITLE>
<body>


<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 6-K</B></P>



<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">For the month of November 2019.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Commission File Number 001-38496</P>



<P STYLE="font: 20pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 20pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Canopy Growth Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name
into English)&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1 Hershey Drive</B></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Smiths Falls, Ontario</B></P>

<P STYLE="font: 11pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>K7A 0A8</B></P>

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive office)</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 30%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/13pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Form 20-F </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Form 40-F </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"></P>




<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 0in 1pt 0.75pt"><DIV STYLE="font-size: 1pt; border-top: gray 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 86%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: black 1pt solid"><B>&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; border-bottom: black 1pt solid; margin-bottom: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Description&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">Ex. 99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">News
    Release dated November 25, 2019 - BC Centre on Substance Use hosts inaugural Cannabis Science Symposium</A> </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0.25in 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/0.05pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 1pt 0in 1pt 0.75pt"><DIV STYLE="font-size: 1pt; border-top: gray 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 11.25pt 0 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 8pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 50%; border-collapse: collapse">
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif; padding-right: 2.8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif; padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CANOPY GROWTH CORPORATION</B></FONT></TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 11%; padding-right: 0.8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-right: 0.8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 77%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.75pt solid">/s/ Phil Shaer</P></TD>
    <TD STYLE="padding-bottom: 8pt; width: 11%; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/107% Calibri, Helvetica, Sans-Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">Phil Shaer</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0 0">Chief Legal Officer</P></TD>
    <TD STYLE="padding-bottom: 8pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Dated: November 25, 2019</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED NOVEMBER 25, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">BC Centre on Substance Use hosts inaugural
Cannabis Science Symposium</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">VANCOUVER, Nov. 25, 2019 /CNW/ -<B>&nbsp;</B>Dr.
M-J Milloy, the Canopy Growth Professor of Cannabis Science at the University of British Columbia (&quot;UBC&quot;) is proud to
bring together patients and other people with lived and living experience with researchers, clinicians, and policymakers for the
inaugural Cannabis Science Symposium with the goal of establishing a research agenda for cannabis and harm reduction during the
overdose crisis.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_002.jpg" ALT="BC Centre on Substance Use hosts inaugural Cannabis Science Symposium (CNW Group|Spectrum Therapeutics)" STYLE="height: 159px; width: 533px"></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">BC
Centre on Substance Use hosts inaugural Cannabis Science Symposium (CNW Group/Spectrum Therapeutics)</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The one-day public research symposium is organized
by the BC Centre on Substance Use (&quot;BCCSU&quot;) and UBC with support from Spectrum Therapeutics, the medical division of
Canopy Growth Corporation (TSX: WEED), (NYSE: CGC).</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In the midst of an ongoing overdose crisis
impacting communities across Canada and the United States, new measures are needed to prevent overdose-related morbidity and mortality,
especially among people living with substance use disorders and common comorbidities, such as chronic pain. A growing wealth of
preliminary evidence suggests cannabis might be a beneficial harm reduction-based intervention. This research symposium will gather
expertise to discuss the latest evidence, reflect on the current responses to the overdose crisis, and establish next steps to
advance knowledge, policy and practice around cannabis for harm reduction.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;The therapeutic benefits of cannabis
are only just beginning to be understood. Early research has shown that it could have a stabilizing impact for people with opioid
use disorder, improving their quality of life and offering a pathway to long-term treatment solutions,&quot; says Dr. Milloy, who
is also a research scientist at BCCSU. &quot;We have a scientific imperative to build upon this research and ensure that research
is guided by the experiences of those living and responding to the overdose crisis.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;This first Cannabis Science Symposium
provides an important forum for researchers, healthcare professionals, community stakeholders and those with lived experience to
exchange knowledge, ideas and first-hand experience on the potential of cannabis in addressing the overdose crisis,&quot; commented
Dr. Mark Ware, Chief Medical Officer, Canopy Growth. &quot;Solutions are still desperately needed and we're committed to doing
our part to help affected individuals, families and communities.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Canopy Growth Professorship of Cannabis
Science was established via a $2.5 million donation from Canopy Growth to UBC and the BCCSU to fund clinical research aimed at
defining the potential benefits of cannabis as a legitimate therapeutic treatment for opioid use disorder. Upon the announcement
of Dr. Milloy as the first Canopy Growth Professor of Cannabis Science, he along with his team performed a comprehensive review
of existing studies examining the role of cannabis in addressing opioid use disorder to help inform the direction of the clinical
trials to be conducted as part of the Professorship.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In their most recent study, where researchers
from the BCCSU and UBC interviewed more than 1,100 people at highest risk of opioid overdose in Vancouver between 2014 and 2017,
it was found that people who used cannabis at least daily had nearly 50 per cent lower odds of using illicit opioids at least daily
compared to cannabis non-users.<SUP>1</SUP> Through their research to date, the BCCSU has demonstrated that the evidence, which
continues to accumulate, supports further evaluation of the therapeutic benefits of cannabis for opioid use disorder.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><U>2019 Cannabis Science Symposium<BR>
</U>&quot;Cannabis and harm reduction: What we know and what we need to learn&quot;<BR>
Monday, November 25, 8:30AM - 1:30PM (Pacific Time)<BR>
UBC Robson Square - 800 Robson St</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The symposium is sold out, however the event
will be broadcasted via webinar. Those interested can register here.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1. Lake, Stephanie, et al. &quot;Frequency of Cannabis and Illicit Opioid Use among People Who Use Drugs and Report Chronic Pain: A Longitudinal Analysis.&quot; <I>PLOS Medicine</I>, Public Library of Science, https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002967.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><U>About BC Centre on Substance Use<BR>
</U></B>The BC Centre on Substance Use (BCCSU) is a provincially networked organization with a mandate to develop, help implement,
and evaluate evidence-based approaches to substance use and addiction. BCCSU seeks to improve the integration of best practices
and care across the continuum of substance use through the collaborative development of evidence-based policies, guidelines, and
standards. With the support of the Province of BC, BCCSU aims to transform substance use policies and care by translating research
into education and care guidance, thereby serving all British Columbians.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><U>About Spectrum Therapeutics<BR>
</U></B>Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: WEED, NYSE: CGC), is dedicated to educating
healthcare practitioners, furthering the public's understanding of medical cannabis and its various applications, and cutting edge,
commercializable research and IP development. Founded in Canada, Spectrum Therapeutics operates in Australia, South America, Africa
and across Europe. Its products are available in a wide range of potencies and formats designed to simplify the dialogue around
strength and dosage by applying a colour-coded spectrum to categorize medical cannabis according to THC and CBD levels. Spectrum
Therapeutics' offerings include whole flower cannabis, oils and new innovations such as Softgels in addition to single cannabinoid
medicine Dronabinol under the brand Bionorica Ethics. Through product simplification, robust clinical research and ongoing education
of healthcare professionals, Spectrum Therapeutics is committed to addressing the unmet medical needs of patients around the globe.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B><U>About Canopy Growth<BR>
</U></B>Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering
distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy
Growth's subsidiary, Storz &amp; Bickel GMbH &amp; Co. KG. From product and process innovation to market execution, Canopy Growth
is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country
at a time. Canopy Growth has operations in over a dozen countries across five continents.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Canopy Growth's medical division, Spectrum
Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the
public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development.
Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as
single cannabinoid Dronabinol under the brand Bionorica Ethics.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Canopy Growth operates retail stores across
Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large
and loyal following by focusing on quality products and meaningful customer relationships. From our historic public listing on
the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder
value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector
names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500
alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over
10.5 million square feet of production capacity, including over one million square feet of GMP certified production space. For
more information visit www.canopygrowth.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Notice Regarding Forward Looking Statements<BR>
</B>This news release contains &quot;forward-looking statements&quot; within the meaning of the United States Private Securities
Litigation Reform Act of 1995 and &quot;forward-looking information&quot; within the meaning of applicable Canadian securities
legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as &quot;plans&quot;,
&quot;expects&quot; or &quot;does not expect&quot;, &quot;is expected&quot;, &quot;estimates&quot;, &quot;intends&quot;, &quot;anticipates&quot;
or &quot;does not anticipate&quot;, or &quot;believes&quot;, or variations of such words and phrases or state that certain actions,
events or results &quot;may&quot;, &quot;could&quot;, &quot;would&quot;, &quot;might&quot; or &quot;will&quot; be taken, occur
or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements or information contained
in this news release. Examples of such statements include establish next steps to advance knowledge, policy and practice around
cannabis for harm reduction. Risks, uncertainties and other factors involved with forward-looking information could cause actual
events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking
information, including research direction, and such risks contained in the Company's annual information form dated June 27, 2018
and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the
Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements
in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that
such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included
in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly
update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise
unless required by applicable securities laws.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:http://www.prnewswire.com/news-releases/bc-centre-on-substance-use-hosts-inaugural-cannabis-science-symposium-300964503.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE Spectrum Therapeutics</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/November2019/25/c9972.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001737927</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Media Contact: British Columbia Centre
on Substance Use, Kevin Hollett, kevin.hollett@bccsu.ubc.ca, 778-918-1537; Canopy Growth, Aly-Khan Virani, alykhan.virani@canopygrowth.com,
236-688-5123</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: Spectrum Therapeutics</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 11:00e 25-NOV-19</P>



<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></p>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "? A4# 2(  A$! Q$!_\0
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MF-)T% Z9JR10/EHZ@BA3Q2GU% AF=O7D4PXSQ4I 9:BJ64@HHHI#"E'!I**
M)8SG-+V!ID1YQ4G53]:M$L0CN*,!A[THXXH90>],0P@K368-P1S3\D<-TH*
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MBF(8=P^[306'K3\^M-.5/'>D,7<#P12X'\+8IN\]Z< &]J #<PZ\THPW3@T
M%:=C/) 'TH 0Y[\B@ #[M([A?4FF>8QXZ47"Q)P?:FEP>&-1]>#24KCL/+ <
M"DW^U-I0OK2N.PN\]J4;F]J48'04#YLG-,D3'IUIRL "#WIC/GA>!2*,FBX[
M#@H[\T[8"/2F\G.*42#^(9HT%J(8]HZTB$C/>I#@C(IHZ46"XPTE/*\4S%)H
M:84444B@I1S24O04" GM2444 %%%+VH 2BEI* "BEHQ0 E%+1B@!,44M)0 4
2444#"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
